SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: IRWIN JAMES FRANKEL who wrote (238)1/27/2005 5:04:20 PM
From: IRWIN JAMES FRANKEL  Read Replies (1) of 447
 
OSIP

I posted this comment and question on Yahoo. I will post the answer if I get one:

Hi Ricardo,

CNBC ran an segment on a doctor with colorectal cancer who was being treated with Erbitux.

They also mentioned that a study supported by Sloan Koettering in 16 patients who did not express EFGR had 4 patients who had greater than 50% shrinkage in tumors and 2 who had less than 50% shrinkage. (Study published in the Journal of Clinical Oncology)

A Dr. L Saltz commented that these findings "blow out of the water the current thinking" that Erbitux should be used for patients expressing EGFR.

This makes me* wonder if we will see a similar advantage to Tarceva that goes beyond the EGFR patients.

Is this reasonable or am I wacky?

ij
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News